Fatty Acid Oxidation Disorders Panel, Sequencing
Ordering Recommendation
New York DOH Approval Status
Specimen Required
Lavender or pink (EDTA)
New York State Clients: Lavender (EDTA)
Transport 3 mL whole blood. (Pediatric Min: 1.5 mL)
New York State Clients: 5 mL (Min: 3 mL)
Refrigerated.
Serum or plasma; grossly hemolyzed or frozen specimens; saliva, buccal brush or swab. FFPE tissue.
Ambient: 72 hours; Refrigerated: 2 weeks; Frozen: Unacceptable
New York State Clients: Ambient: 48 hours; Refrigerated: 1 week; Frozen: Unacceptable
Methodology
Massively Parallel Sequencing
Performed
Varies
Reported
10-15 days
Reference Interval
By report
Interpretive Data
Refer to report.
This test was developed, and its performance characteristics determined, by ARUP Laboratories. It has not been cleared or approved by the U.S. Food and Drug Administration. This test was performed in a CLIA-certified laboratory and is intended for clinical purposes.
Counseling and informed consent are recommended for genetic testing. Consent forms are available online.
Laboratory Developed Test (LDT)
Note
Genes tested: ACAD9, ACADM, ACADS, ACADVL, ACAT1, CPT1A, CPT2, ECHS1, ETFA, ETFB, ETFDH, FLAD1, HADH, HADHA, HADHB, HMGCL, HMGCS2, HSD17B10, LPIN1*, MLYCD, SLC22A5, SLC25A20, SLC52A1, SLC52A2, SLC52A3.
*One or more exons are not covered by sequencing for the indicated gene; see Additional Technical Information
Hotline History
CPT Codes
81404; 81405; 81406; 81479
Components
Component Test Code* | Component Chart Name | LOINC |
---|---|---|
3001852 | Fatty Acid Oxidation Disorders Specimen | |
3001853 | Fatty Acid Oxidation Disorders Interp |
Aliases
- trifunctional protein deficiency
- ECHS1 deficiency
- MCAD deficiency
- riboflavin transporter deficiency 3
- riboflavin deficiency
- riboflavin transporter deficiency 1
- riboflavin transporter deficiency 2
- acute recurrent myoglobinuria
- mitochondrial complex I deficiency
- mitochondrial short-chain enoyl-CoA hydratase 1 deficiency
- elevated liver enzymes
- systemic primary carnitine deficiency
- T2 deficiency
- VLCAD deficiency
- Brown-Vialetto-Van-Laere syndrome 2
- beta-ketothiolase deficiency
- CACT deficiency
- and low platelet (HELLP) syndromes
- Brown-Vialetto-Van-Laere syndrome 1
- carnitine uptake defect
- congenital hyperinsulinism
- CPT II deficiency
- CPT1A deficiency
- familial hyperinsulinemic hypoglycemia
- Fatty acid oxidation disorders
- Fazio-Londe syndrome
- GA2
- GAII
- glutaric acidemia II
- glutaric aciduria II
- HADH deficiency
- HMG-CoA lyase deficiency
- HMG-CoA synthase-2 deficiency
- primary carnitine deficiency
- HSD10 mitochondrial disease
- LCHAD deficiency
- lipid storage myopathy
- LPIN1 deficiency
- MADD type I
- MADD type II
- MADD type III
- MADD-like illness
- malonyl-CoA decarboxylase deficiency
- MAT deficiency
- MLYCD deficiency
- multiple acyl-CoA dehydrogenase deficiency
- persistent hyperinsulinemic hypoglycemia of infancy (PHHI)
- carnitine-acylcarnitine translocase deficiency
- ACAD9 deficiency
- ACADM deficiency
- ACADS deficiency
- acute fatty liver pregnancy (AFLP)
- carnitine transport defect
- flavin adenine dinucleotide synthetase deficiency
- HSD17B10 deficiency
- hypertension
- fatty acid oxidation defects
- SCAD deficiency